Activated partial thromboplastin time following Kcentra® versus Balfaxar® reversal of apixaban, rivaroxaban, and warfarin: a propensity-matched cohort study
Publication date: Available online 11 November 2026 Source: The American Journal of Emergency Medicine Author(s): Nataly A. Guirguis, Elizabeth A. Feldman, Patrick G. Rose, Christopher D. Miller, Robert W. Seabury
Activated partial thromboplastin time following Kcentra® versus Balfaxar® reversal of apixaban, rivaroxaban, and warfarin: a propensity-matched cohort study. // American Journal of Emergency Medicine. – URL: https://www.sciencedirect.com/science/article/pii/S0735675726005978?dgcid=rss_sd_all
Activated partial thromboplastin time following Kcentra® versus Balfaxar® reversal of apixaban, rivaroxaban, and warfarin: a propensity-matched cohort study. American Journal of Emergency Medicine. https://www.sciencedirect.com/science/article/pii/S0735675726005978?dgcid=rss_sd_all
“Activated partial thromboplastin time following Kcentra® versus Balfaxar® reversal of apixaban, rivaroxaban, and warfarin: a propensity-matched cohort study.” American Journal of Emergency Medicine.
@article{article34624,
title = {Activated partial thromboplastin time following Kcentra® versus Balfaxar® reversal of apixaban, rivaroxaban, and warfarin: a propensity-matched cohort study},
journal = {American Journal of Emergency Medicine},
url = {https://www.sciencedirect.com/science/article/pii/S0735675726005978?dgcid=rss_sd_all}
}